Format

Send to

Choose Destination
  • The following term was not found in PubMed: lupus-2018-000294.
Laryngorhinootologie. 2017 Aug;96(8):519-521. doi: 10.1055/s-0043-113690. Epub 2017 Aug 29.

Die Behandlung des M. Menière mit Betahistin: Kritische Anmerkungen zur BEMED-Studie.

[Article in German; Abstract available in German from the publisher]

Author information

1
HNO-Klinik im ukb.
2
Hals-Nasen-Ohren-Klinik, Kopf- und Halschirurgie, Universitätsklinikum Erlangen.
3
HNO-Univ.klinik der RWTH Aachen.

Abstract

in English, German

The BEMED study (BMJ 2016; 352: DOI 10.1136) was designed as multi-centric, double-blind, plaebo-controlled study in patients with Menière's disease. It should compare a low-level (2 × 24 mg/d) vs. high-level (3 × 48 mg/d) betahstine intake vs. placebo. The primary endpoint was the "number of vertigo attacks lasting longer than 20 min as documented in a patient's diary". The main finding of the study was that betahistine did not significantly better reduced the number of vertigo attacks than placebo. Therefore, the BEMED study should be critically discussed in the present paper.

PMID:
28850992
DOI:
10.1055/s-0043-113690
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York Icon for Digital CSIC Spanish National Research Council
Loading ...
Support Center